Toggle Main Menu Toggle Search

Open Access padlockePrints

Renal effects of amlodipine in normotensive renal transplant recipients

Lookup NU author(s): Professor Robert Wilkinson

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Renal effects of amlodipine in normotensive renal transplant recipients. The use of cyclosporin A (CsA) has improved the success of renal transplantation, but is associated with hypertension and significant renal toxicity. Previous reports suggest that calcium channel blockers may be useful in opposing the adverse effects of CsA. We have evaluated the effects of amlodipine (5 mg, once daily for 8 weeks) on renal function in 27 normotensive renal transplant recipients with stable renal function, in a double-blind, placebo-controlled, multicentre, cross over study. Amlodipine significantly reduced serum creatinine concentration relative to placebo (mean+/-SD: 168+/-65 vs 177+/- 66 mu mol/l; P=0.002) and there was a strong trend towards an increase in effective renal plasma flow on amlodipine relative to placebo (238+/-92 vs 217+/-87 ml/min; P=0.055). Glomerular filtration rate and lithium clearance were unaffected. Trough CsA brood concentration was unaffected. Amlodipine was well tolerated, with a low incidence of adverse events, and did not affect blood pressure or heart rate. In conclusion, amlodipine reduced serum creatinine in normotensive renal transplant recipients after only 8 weeks treatment, and was well tolerated in concomitant administration with CsA.


Publication metadata

Author(s): Wilkinson R; Raman GV; Feehally J; Coates RA; Elliott HL; Griffin PJA; Olubodun JOB

Publication type: Article

Publication status: Published

Journal: Nephrology Dialysis Transplantation

Year: 1999

Volume: 14

Issue: 2

Pages: 384-388

Print publication date: 01/02/1999

ISSN (print): 0931-0509

ISSN (electronic): 1460-2385

Publisher: Oxford University Press

URL: http://dx.doi.org/10.1093/ndt/14.2.384

DOI: 10.1093/ndt/14.2.384


Altmetrics

Altmetrics provided by Altmetric


Share